Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia

被引:0
|
作者
Kraft, Leticia [1 ]
Ribeiro, Victoria Stadler Tasca [1 ]
Goncalves, Geiziane Aparecida [1 ]
Suss, Paula Hansen [1 ]
Tuon, Felipe Francisco [1 ]
机构
[1] Pontificia Univ Catolica Parana, Sch Med, Dept Hlth Sci, Lab Emerging Infect Dis, Curitiba, Parana, Brazil
来源
关键词
Antifungals; Candida; Candidemia; Breakthrough candidemia; Biofilms; VENOUS CATHETER INFECTIONS; IN-VITRO EFFECTIVENESS; RISK-FACTORS; HEMATOLOGICAL MALIGNANCIES; ANTIFUNGAL SUSCEPTIBILITY; FORMULATIONS; THERAPY; MODEL; SPP; ERA;
D O I
10.1016/j.eimc.2022.07.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Biofilm formation causes virulence and resistance in Candida albicans. However, little is known about breakthrough candidemia isolates. We evaluated the antifungal activity of fluconazole, anidulafungin, deoxycholate amphotericin B (dAMB), and amphotericin B lipid complex (ABLC) against biofilms of C. albicans isolated from patients with breakthrough candidemia. Methods: The present study used strains of C. albicans isolated from breakthrough and non-breakthrough candidemia patients (control group). The susceptibility of planktonic cells to amphotericin B, anidulafungin, and fluconazole was determined by broth microdilution. Antifungal activity in sessile cells was evaluated using the minimum biofilm eradication concentration (MBEC), metabolic activity was estimated by reducing MTT, and biomass was estimated using crystal violet retention. Results: The planktonic strains were susceptible to amphotericin B, anidulafungin, and fluconazole, with minimum inhibitory concentrations of 1, <= 0.03, and 2 mg/L, respectively. However, fluconazole and anidulafungin did not exert an antifungal effect on biofilms. Additionally, dAMB and ABCL reduced the metabolic activity and biomass. However, eradication was only achieved using 16 mg/L dAMB. C. albicans isolates of breakthrough candidemia exhibited strong biofilm production, and the in vitro activity of available therapeutic options was poor. Conclusion: In the present study, only dAMB and ABCL exhibited antibiofilm effects against sessile breakthrough candidemia isolates. (c) 2022 Published by Elsevier Espan similar to a, S.L.U. on behalf of Sociedad Espan similar to ola de Enfermedades Infecciosas y Microbiologi ' a Cli ' nica.
引用
收藏
页码:596 / 603
页数:8
相关论文
共 50 条
  • [1] In vitro activity of amphotericin B and anidulafungin against Candida albicans biofilms
    Valentin, A.
    Canton, E.
    Peman, J.
    Bosch, M.
    Eraso, E.
    Gobernado, M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S562 - S562
  • [2] Biofilm Formation and Susceptibility to Amphotericin B and Fluconazole in Candida albicans
    Mahmoudabadi, Ali Zarei
    Zarrin, Majid
    Kiasat, Neda
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2014, 7 (07)
  • [3] Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus
    Al-Nakeeb, Zaid
    Petraitis, Vidmantas
    Goodwin, Joanne
    Petraitiene, Ruta
    Walsh, Thomas J.
    Hope, William W.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (05) : 2735 - 2745
  • [4] Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans
    Burgess, DS
    Hastings, RW
    Summers, KK
    Hardin, TC
    Rinaldi, MG
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) : 13 - 18
  • [5] Antifungal activity of carvacrol in combination with fluconazole or amphotericin B against Candida albicans
    Khodavandi, Alireza
    Alizadeh, Fahimeh
    Alizadeh, Eskandar
    MALAYSIAN JOURNAL OF MICROBIOLOGY, 2018, 14 (05) : 356 - 363
  • [6] Comparison of the effects of deoxycholate amphotericin B and amphotericin B lipid complex on the gene exression of inflammatory cytokines and receptors in human monocytes exposed to Candida albicans
    Simitsopoulou, M.
    Georgiadou, E.
    Walsh, T. J.
    Roilides, E.
    MYCOSES, 2009, 52 : 98 - 98
  • [7] Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex
    Ozaras, Resat
    Yemisen, Mucahit
    Mete, Bilgul
    Mert, Ali
    Ozturk, Recep
    Tabak, Fehmi
    MYCOSES, 2007, 50 (03) : 242 - 242
  • [8] Biliary excretion of amphotericin B deoxycholate and amphotericin B lipid complex
    Duflo, F
    Allaouchiche, B
    Chassard, D
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2000, 32 (05) : 581 - 581
  • [9] Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole
    Carrillo-Muñoz, AJ
    Quindós, G
    Tur, C
    Ruesga, M
    Alonso, R
    del Valle, O
    Rodriguez, V
    Arévalo, MP
    Salgado, J
    Martin-Mazuelos, E
    Bornay-Llinares, FJ
    del Palacio, A
    Cuétara, M
    Gasser, I
    Hernández-Molina, JM
    Pemán, J
    CHEMOTHERAPY, 2000, 46 (04) : 235 - 244
  • [10] In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates
    Oz, Yasemin
    Aksit, Filiz
    Kiraz, Nuri
    Kiremitci, Abdurrahman
    MIKROBIYOLOJI BULTENI, 2008, 42 (01): : 149 - 155